Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

395 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Is HPS2-THRIVE the death knell for niacin?
Toth PP, Murthy AM, Sidhu MS, Boden WE. Toth PP, et al. Among authors: boden we. J Clin Lipidol. 2015 May-Jun;9(3):343-50. doi: 10.1016/j.jacl.2015.01.008. Epub 2015 Jan 30. J Clin Lipidol. 2015. PMID: 26073392 Review.
The therapeutic role of niacin in dyslipidemia management.
Boden WE, Sidhu MS, Toth PP. Boden WE, et al. J Cardiovasc Pharmacol Ther. 2014 Mar;19(2):141-58. doi: 10.1177/1074248413514481. Epub 2013 Dec 20. J Cardiovasc Pharmacol Ther. 2014. PMID: 24363242 Review.
The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol Rationale and study design. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: Impact on Global Health outcomes (AIM-HIGH).
AIM-HIGH Investigators. AIM-HIGH Investigators. Am Heart J. 2011 Mar;161(3):471-477.e2. doi: 10.1016/j.ahj.2010.11.017. Epub 2011 Feb 2. Am Heart J. 2011. PMID: 21392600 Free PMC article. Clinical Trial.
Effects of Extended-Release Niacin on Quartile Lp-PLA2 Levels and Clinical Outcomes in Statin-treated Patients with Established Cardiovascular Disease and Low Baseline Levels of HDL-Cholesterol: Post Hoc Analysis of the AIM HIGH Trial.
Lyubarova R, Albers JJ, Marcovina SM, Yao Y, McBride R, Topliceanu A, Anderson T, Fleg JL, Desvigne-Nickens P, Kashyap ML, McGovern ME, Boden WE. Lyubarova R, et al. Among authors: boden we. J Cardiovasc Pharmacol Ther. 2019 Nov;24(6):534-541. doi: 10.1177/1074248419852955. Epub 2019 May 26. J Cardiovasc Pharmacol Ther. 2019. PMID: 31131629 Clinical Trial.
Effect of baseline exercise capacity on outcomes in patients with stable coronary heart disease (a post hoc analysis of the clinical outcomes utilizing revascularization and aggressive drug evaluation trial).
Padala SK, Sidhu MS, Hartigan PM, Maron DJ, Teo KK, Spertus JA, Mancini GB, Sedlis SP, Chaitman BR, Heller GV, Weintraub WS, Boden WE. Padala SK, et al. Among authors: boden we. Am J Cardiol. 2015 Nov 15;116(10):1509-15. doi: 10.1016/j.amjcard.2015.08.012. Epub 2015 Aug 31. Am J Cardiol. 2015. PMID: 26410604 Free PMC article. Clinical Trial.
Causes of cardiovascular and noncardiovascular death in the ISCHEMIA trial.
Sidhu MS, Alexander KP, Huang Z, O'Brien SM, Chaitman BR, Stone GW, Newman JD, Boden WE, Maggioni AP, Steg PG, Ferguson TB, Demkow M, Peteiro J, Wander GS, Phaneuf DC, De Belder MA, Doerr R, Alexanderson-Rosas E, Polanczyk CA, Henriksen PA, Conway DSG, Miro V, Sharir T, Lopes RD, Min JK, Berman DS, Rockhold FW, Balter S, Borrego D, Rosenberg YD, Bangalore S, Reynolds HR, Hochman JS, Maron DJ; ISCHEMIA Research Group. Sidhu MS, et al. Among authors: boden we. Am Heart J. 2022 Jun;248:72-83. doi: 10.1016/j.ahj.2022.01.017. Epub 2022 Feb 9. Am Heart J. 2022. PMID: 35149037 Free PMC article. Clinical Trial.
Cardiovascular outcomes during extended follow-up of the AIM-HIGH trial cohort.
Probstfield JL, Boden WE, Anderson T, Branch K, Kashyap M, Fleg JL, Desvigne-Nickens P, McBride R, McGovern M; AIM-HIGH Investigators. Probstfield JL, et al. Among authors: boden we. J Clin Lipidol. 2018 Nov-Dec;12(6):1413-1419. doi: 10.1016/j.jacl.2018.07.007. Epub 2018 Jul 25. J Clin Lipidol. 2018. PMID: 30131256
Relations of GlycA and lipoprotein particle subspecies with cardiovascular events and mortality: A post hoc analysis of the AIM-HIGH trial.
Otvos JD, Guyton JR, Connelly MA, Akapame S, Bittner V, Kopecky SL, Lacy M, Marcovina SM, Muhlestein JB, Boden WE. Otvos JD, et al. Among authors: boden we. J Clin Lipidol. 2018 Mar-Apr;12(2):348-355.e2. doi: 10.1016/j.jacl.2018.01.002. Epub 2018 Jan 12. J Clin Lipidol. 2018. PMID: 29409728 Free PMC article. Clinical Trial.
395 results